Group statistics of selected clinical and laboratory test results.
| SLE, n = 42 | Control, n = 19 | p | |
|---|---|---|---|
| Demographic | |||
| Age, yrs, mean ± SD | 37.3 ± 12.8 | 31.9 ± 10.1 | 0.11 |
| Female, % | 95 | 89 | 0.58 |
| Body composition | |||
| Weight, kg | 72.0 ± 12.7 | 72.1 ± 12.8 | 0.96 |
| BMI, kg/m2 | 26.9 ± 4.8 | 26.8 ± 6.0 | 0.97 |
| Blood pressure, mm Hg | |||
| Mean arterial | 91.9 ± 10.1 | 87.1 ± 5.7 | 0.02 |
| Systolic | 123.8 ± 13.9 | 116.0 ± 8.0 | < 0.01 |
| Diastolic | 76.0 ± 10.2 | 72.7 ± 6.5 | 0.13 |
| Blood composition | |||
| Hematocrit, % | 38 ± 4 | 40 ± 3 | 0.07 |
| White blood cell count, k/ml | 5.8 ± 2.4 | 6.5 ± 1.8 | 0.25 |
| Red blood cell count, k/ml | 4.3 ± 0.5 | 4.6 ± 0.3 | < 0.01 |
| Blood urea nitrogen, mg/dl | 15.2 ± 4.9 | 12.3 ± 3.4 | 0.02 |
| Creatine, mg/dl | 0.82 ± 0.30 | 0.71 ± 0.10 | 0.04 |
| Triglyceride, mg/dl | 139.9 ± 59.3 | 144.6 ± 87.5 | 0.83 |
| Cholesterol, mg/dl | 177.4 ± 40.1 | 179.8 ± 42.2 | 0.85 |
| Hemoglobin, g/dl | 13.1 ± 1.6 | 13.8 ± 1.34 | 0.10 |
| Inflammation factors | |||
| C5a, pg/ml | 30.2 ± 11.4 | 29.8 ± 10.1 | 0.91 |
| C3a, pg/ml | 2118 ± 3253 | 1932 ± 2121 | 0.82 |
| Monocyte CD14 microparticles, μl−1 | 436 ± 700 | 476 ± 509 | 0.82 |
| Thrombogenisis | |||
| Platelets, k/ml | 239 ± 86 | 275 ± 43 | 0.04 |
| tPA, units/ml | 9.1 ± 4.1 | 7.4 ± 4.4 | 0.15 |
| Plasminogen activator inhibitor 1, units/ml | 11.0 ± 13.3 | 18.4 ± 37.8 | 0.40 |
| Tissue factor positive microparticles μl−1 | 204 ± 323 | 236 ± 230 | 0.70 |
| Platelet CD41 microparticles μl−1 | 639 ± 763 | 542 ± 617 | 0.63 |
| Annexin positive microparticles μl−1 | 651 ± 755 | 559 ± 561 | 0.64 |
| Other microparticles | |||
| Total microparticles, μl | 2716 ± 1691 | 2661 ± 1125 | 0.90 |
| Endothelium CD144 microparticles, μl−1 | 157 ± 247 | 153 ± 125 | 0.94 |
BMI: body mass index; tPA: tissue plasminogen activator; SLE: systemic lupus erythematosus.